PE20091926A1 - Acido l-glutamico y derivado l-glutamina (iii) y metodo para obtenerlos - Google Patents

Acido l-glutamico y derivado l-glutamina (iii) y metodo para obtenerlos

Info

Publication number
PE20091926A1
PE20091926A1 PE2009000708A PE2009000708A PE20091926A1 PE 20091926 A1 PE20091926 A1 PE 20091926A1 PE 2009000708 A PE2009000708 A PE 2009000708A PE 2009000708 A PE2009000708 A PE 2009000708A PE 20091926 A1 PE20091926 A1 PE 20091926A1
Authority
PE
Peru
Prior art keywords
glutamic acid
glutamine
acid
derivative
iii
Prior art date
Application number
PE2009000708A
Other languages
English (en)
Inventor
Ludger Dinkelborg
Heribert Schmitt-Willich
Keith Andrew Newton Graham
Norman Koglin
Mathias Berndt
Matthias Friebe
Andre Muller
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20091926A1 publication Critical patent/PE20091926A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pyridine Compounds (AREA)

Abstract

REFERIDA A UN ACIDO GLUTAMICO FLUORADO Y DERIVADOS DE L-GLUTAMINA EN DONDE SE INCORPORA UN 19F DE FORMULA (I), DONDE A ES OH, NH2, ALCOXI C1-C5, ENTRE OTROS; G ES OH, -O-ALQUILO C1-C5, -O-ALQUINILO C2-C5, ENTRE OTROS; R1 Y R2 SON H, 19F-ALCOXI C1-C10, 19F-ALQUENILO C2-C10, 19F-ARILO C6-C10, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO (2S,4S)-2-AMINO-4-(3-FLUOROPROPIL)-PENTANODIOICO, ACIDO 2-AMINO-4-(6-FLUOROHEXIL)-PENTANODIOICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS Y PARA EL DIAGNOSTICO POR IMAGENES DE RESONANCIA MAGNETICA (MIR)
PE2009000708A 2008-05-20 2009-05-20 Acido l-glutamico y derivado l-glutamina (iii) y metodo para obtenerlos PE20091926A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08075509A EP2123620A1 (en) 2008-05-20 2008-05-20 {F-19}-labeled L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them

Publications (1)

Publication Number Publication Date
PE20091926A1 true PE20091926A1 (es) 2010-01-24

Family

ID=39967400

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000708A PE20091926A1 (es) 2008-05-20 2009-05-20 Acido l-glutamico y derivado l-glutamina (iii) y metodo para obtenerlos

Country Status (11)

Country Link
US (2) US20110064673A1 (es)
EP (2) EP2123620A1 (es)
JP (1) JP2011520931A (es)
KR (1) KR20110013411A (es)
CN (1) CN102083773A (es)
AR (1) AR073844A1 (es)
CA (1) CA2723594A1 (es)
PE (1) PE20091926A1 (es)
TW (1) TW201010733A (es)
UY (1) UY31834A (es)
WO (1) WO2009141090A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123621A1 (de) 2008-05-20 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Neue {F-18}-markierte L-Glutaminsäure- und L-Glutaminderivate (I), ihre Verwendung sowie Verfahren zu ihrer Herstellung
US20100217011A1 (en) 2006-11-01 2010-08-26 Bayer Schering Pharma Aktiengesellschaft [f-18]-labeled l-glutamic acid, [f-18]-labeled l-glutamine, derivatives thereof and use thereof and processes for their preparation
EP2464223A1 (en) * 2009-08-14 2012-06-20 The Trustees Of The University Of Pennsylvania Single diastereomers of 4-fluoroglutamine and methods for their preparation and use
EP2322171A3 (en) * 2009-11-17 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Fluorine labeled L-glutamic acid derivatives
MX2012005733A (es) * 2009-11-17 2013-01-22 Bayer Ip Gmbh Metodo de produccion de derivados de acido glutamico marcados con f-18.
EP2520556A1 (en) * 2011-05-03 2012-11-07 Bayer Pharma Aktiengesellschaft Radiolabeled amino acids for diagnostic imaging
EP2520557A1 (en) 2011-05-03 2012-11-07 Bayer Pharma Aktiengesellschaft Novel precursors of glutamate derivatives
CN103333079B (zh) * 2013-07-03 2016-08-17 广东回旋医药科技股份有限公司 亚氨基酸类pet显像剂及其制备方法与应用
CN109467514B (zh) * 2018-11-15 2020-11-24 西北师范大学 一种α-胺基-γ-羰基庚二酸酯类化合物的合成方法
CN109369445B (zh) * 2018-11-20 2021-10-15 首都医科大学 用于诊断和治疗的放射性谷氨酰胺衍生物及其制备方法
MX2021007272A (es) * 2018-12-18 2021-09-23 Xianfeng Peng Aplicacion de un derivado de la glutamina en la preparacion de aditivos para alimentos de animales.
US20220267255A1 (en) * 2019-07-12 2022-08-25 University Of Mississippi L-y-methyleneglutamine compounds and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9324872D0 (en) * 1993-12-03 1994-01-19 Univ Pasteur Pharmaceutical compounds
US5721265A (en) * 1994-08-05 1998-02-24 Sri International Fluorinated 2-nitroimidazole analogs for detecting hypoxic tumor cells
WO2002014261A2 (en) * 2000-08-10 2002-02-21 Eli Lilly And Company 4-substituted d-glutamic acid derivatives for use as antibiotic
CA2421507A1 (en) * 2000-09-01 2002-03-07 Karina Aprico Screen for glutamate reuptake inhibitors, stimulators, and modulators
CA2494704A1 (en) * 2002-08-02 2004-12-23 Mallinckrodt Inc. Radioactively labelled amino acid analogues, their preparation and use
US7483732B2 (en) * 2004-04-15 2009-01-27 Boston Scientific Scimed, Inc. Magnetic resonance imaging of a medical device and proximate body tissue
CA2612186A1 (en) * 2005-06-23 2007-01-04 Emory University Imaging agents
US20100217011A1 (en) * 2006-11-01 2010-08-26 Bayer Schering Pharma Aktiengesellschaft [f-18]-labeled l-glutamic acid, [f-18]-labeled l-glutamine, derivatives thereof and use thereof and processes for their preparation

Also Published As

Publication number Publication date
CN102083773A (zh) 2011-06-01
JP2011520931A (ja) 2011-07-21
US20140227191A1 (en) 2014-08-14
EP2123620A1 (en) 2009-11-25
US20110064673A1 (en) 2011-03-17
WO2009141090A8 (en) 2010-10-28
KR20110013411A (ko) 2011-02-09
WO2009141090A9 (en) 2010-03-25
EP2282981A1 (en) 2011-02-16
WO2009141090A1 (en) 2009-11-26
TW201010733A (en) 2010-03-16
UY31834A (es) 2010-01-05
AR073844A1 (es) 2010-12-09
CA2723594A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
PE20091926A1 (es) Acido l-glutamico y derivado l-glutamina (iii) y metodo para obtenerlos
CY1118439T1 (el) Νεοι συγκρυσταλλοι αγομελατινης
CY1121143T1 (el) Χρηση pde7 αναστολεων για την αντιμετωπιση κινητικων διαταραχων
PE20091888A1 (es) Inhibidores de catepsina c
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
CR20130333A (es) Compuestos indol o análogos de los mismos útiles en el tratamiento de la degeneración macular relacionada con la edad (dmae)
PE20141322A1 (es) Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina
EA201001766A1 (ru) Новые[f-18]-меченые производные l-глутаминовой кислоты и l-глутамина (i), их применение, а также способ их получения
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
ECSP11011008A (es) Proceso para la preparación de derivados de l-alanina protegidos
CO6382154A2 (es) Sales de fingolimod
UY31803A (es) Compuesto cristalino
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
ECSP10010498A (es) Procesos para la preparación de derivados de heteroarilo benzofusionados
PE20141199A1 (es) Depsipeptidos ciclicos como moduladores de calicreina 7
NI201000157A (es) Inhibidores desacetilasas b a base de hidroxamato.
EA201190293A1 (ru) Пролекарства триптолида
CO7350641A2 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados
BRPI0817747A8 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
ECSP10010499A (es) Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida
AR117002A2 (es) Proceso para la preparación de inhibidores de quinasa c-fms
EA200900732A1 (ru) Кристаллическая калиевая соль аналогов липоксина а
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
AR075097A1 (es) Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal